Rekovar Inc.

Lake Forest, CA

UEI
EJX5YKMCKG35
CAGE
87J09
Primary NAICS
334510 Electromedical and Electrotherapeutic Apparatus Manufacturing
SAM.gov registration
Active through

Company facts

SBA certifications
Women-Owned Small Business
· Current
Self-certified in SAM.gov
  • For Profit Organization
  • Woman Owned Small Business
  • Woman Owned Business
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
21 Spectrum Pointe Dr #101, Lake Forest, CA 92630, USA
Website
rekovar.com
Founded
2018
Employees
1-10
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Health Care Equipment & Services
  3. Health Care Providers & Services
  4. Health Care Services
SIC code
80 Health Services
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Rekovar Inc.'s 3 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Wireless wearable with AI analytics for monitoring neonatal abstinence syndrome (NAS) - project summary neonatal… Grant · R44DA060640 National Institute on Drug Abuse $411,800
Wireless withdrawal detection and monitoring system for neonatal abstinence syndrome. - project summary neonatal… Grant · R44DA049615 National Institute on Drug Abuse $8,078,061
Wireless withdrawal detection and monitoring system for neonatal abstinence syndrome. Grant · R41DA049615 National Institute on Drug Abuse $390,000

About Rekovar Inc.

Rekovar Inc. is a woman-owned small business based in Lake Forest, California, registered in the System for Award Management (SAM) since November 2018. The company appears to specialize in developing advanced medical technology solutions, with a particular focus on innovative healthcare monitoring devices utilizing artificial intelligence and biosensor technologies. As a corporate entity, Rekovar Inc. has positioned itself as a technological innovator in the healthcare sector, specifically targeting neonatal and pediatric medical challenges.

The company has been awarded multiple federal grants from the National Institute on Drug Abuse (NIDA) focused on developing a wireless wearable monitoring system called NeoMonki for assessing Neonatal Abstinence Syndrome (NAS). These grants, totaling approximately $411,800, support the development of a comprehensive medical monitoring kit that includes wearable wristbands with biosensor technology, a tablet-based healthcare portal, a charging dock station, and an imaging camera. The core innovation of their technology is an AI-driven clinical algorithm designed to continuously monitor and analyze physiological symptoms of newborns experiencing NAS, with the ultimate goal of improving diagnostic precision, reducing hospital stays, and potentially obtaining FDA de novo approval. The grants have supported two primary phases of research and development, with the most recent award in February 2025 focusing on further refining the AI algorithm and conducting clinical trials to validate the NeoMonki system's effectiveness in digital NAS assessment and treatment.

Quick answers

What is Rekovar Inc.'s UEI?

Rekovar Inc.'s Unique Entity ID (UEI) in SAM.gov is EJX5YKMCKG35.

What is Rekovar Inc.'s CAGE code?

Rekovar Inc.'s CAGE code is 87J09.

What is Rekovar Inc.'s primary NAICS code?

Rekovar Inc.'s primary NAICS code is 334510 (Electromedical and Electrotherapeutic Apparatus Manufacturing).

Where is Rekovar Inc. located?

Rekovar Inc.'s physical address in SAM.gov is 21 Spectrum Pointe Dr #101, Lake Forest, CA 92630, USA.

Is Rekovar Inc. registered in SAM.gov?

Yes. Rekovar Inc.'s SAM.gov registration is active through January 1, 2027.

Which SBA certifications does Rekovar Inc. hold?

Rekovar Inc. holds Women-Owned Small Business certification from the SBA.

What is Rekovar Inc.'s most recent federal award?

Rekovar Inc.'s most recent federal grant award is Wireless wearable with AI analytics for monitoring neonatal abstinence syndrome (NAS) - project summary neonatal… (R44DA060640), from National Institute on Drug Abuse, on February 1, 2025.

On GovTribe

See Rekovar Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors